Study of IDO Inhibitor in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Cancer
Lumos Pharma
Lumos Pharma
Asan Medical Center
Centre Oscar Lambret
Centre Oscar Lambret
Ankara University
Incheon St.Mary's Hospital
Shanghai Cancer Hospital, China
Delfi Diagnostics Inc.
University of Kentucky
UNICANCER
Regeneron Pharmaceuticals
Karolinska University Hospital
University of Iowa
Abramson Cancer Center at Penn Medicine
University of Pennsylvania
Grupo Espanol de Tumores Neuroendocrinos
Columbia University
Hoffmann-La Roche
Immuneering Corporation
Memorial Sloan Kettering Cancer Center
Imugene Limited
Eurofarma Laboratorios S.A.
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Astellas Pharma Inc
AstraZeneca
Astellas Pharma Inc
European Organisation for Research and Treatment of Cancer - EORTC
CancerCare Manitoba
Merck Sharp & Dohme LLC
Imunon
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Advaxis, Inc.
Icahn School of Medicine at Mount Sinai
Morphotek
Mural Oncology, Inc
Columbia University
Renmin Hospital of Wuhan University
ZielBio, Inc.
HonorHealth Research Institute
Sumitomo Pharma America, Inc.
Sumitomo Pharma America, Inc.
Medical College of Wisconsin
National Institutes of Health Clinical Center (CC)
H. Lee Moffitt Cancer Center and Research Institute
Cantargia AB
Celgene